| 5.71 0.24 (4.39%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.6  |
1-year : | 8.88 |
| Resists | First : | 6.51 |
Second : | 7.6 |
| Pivot price | 5.77  |
|||
| Supports | First : | 5.25 |
Second : | 4.46 |
| MAs | MA(5) : | 5.64 |
MA(20) : | 5.65 |
| MA(100) : | 4.39 |
MA(250) : | 3.36 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 26.1 |
D(3) : | 37.2 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 6.51 | Low : | 1.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ABCL ] has closed above bottom band by 42.0%. Bollinger Bands are 35.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.76 - 5.79 | 5.79 - 5.82 |
| Low: | 5.37 - 5.41 | 5.41 - 5.45 |
| Close: | 5.65 - 5.71 | 5.71 - 5.77 |
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Tue, 21 Oct 2025
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Insider Monkey
Tue, 21 Oct 2025
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Yahoo Finance
Fri, 17 Oct 2025
AbCellera Biologics Inc. (ABCL) Stock Analysis: A 59.82% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Tue, 07 Oct 2025
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 - Investing News Network
Mon, 06 Oct 2025
AbCellera Biologics: Entering Growth Phase After A Pause (NASDAQ:ABCL) - Seeking Alpha
Sun, 05 Oct 2025
AbCellera Biologics (ABCL) Is Up 24.5% After Milestone Revenue Beat and First Clinical Trial Launch Has the Bull Case Changed? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 299 (M) |
| Shares Float | 203 (M) |
| Held by Insiders | 22.9 (%) |
| Held by Institutions | 38.4 (%) |
| Shares Short | 46,140 (K) |
| Shares Short P.Month | 43,230 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.4 |
| Profit Margin | 0 % |
| Operating Margin | -290.3 % |
| Return on Assets (ttm) | -11 % |
| Return on Equity (ttm) | -15.7 % |
| Qtrly Rev. Growth | 133.3 % |
| Gross Profit (p.s.) | -0.46 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -0.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -208 (M) |
| PE Ratio | -10.2 |
| PEG Ratio | 0 |
| Price to Book value | 1.67 |
| Price to Sales | 51.89 |
| Price to Cash Flow | -21.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|